PYC Therapeutics Says ADOA Patients Show Sustained Visual Acuity, Retinal Stress Improvements in Drug Candidate Trials

MT Newswires Live07-21

PYC Therapeutics (ASX:PYC) said autosomal dominant optic atrophy (ADOA) patients in the ongoing clinical trials of its PYC-001 drug candidate showed sustained improvement in both visual acuity and retinal stress following repeat doses, according to a Tuesday Australian bourse filing.

Non-human primates treated with a single dose of the candidate at 15 micrograms per eye showed a sustained increase in OPA1 protein target gene expression in the retina four months after a single treatment.

Human patients are currently receiving the candidate once every two to three months. The data from non-human primates support extending the dosing interval to once every four months or more. The firm plans to review the clinical protocol for the ongoing studies with a view to extending the dosing interval in these trials.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment